Allogene Therapeutics (ALLO) Proxy filing summary

Executive summary

• Appointment of Zachary Roberts, M.D., Ph.D. as President and CEO effective July 1, 2026, succeeding David Chang, M.D., Ph.D.

• Dr. Roberts will also join the Board as a Class I director, serving until the 2028 annual meeting.

• Dr. Chang will transition to a non-employee director role and receive compensation per the non-employee director policy.

Voting matters and shareholder proposals

• No changes to proxy cards; previously submitted votes remain valid for the June 18, 2026 annual meeting.

• Instructions for voting, changing, or revoking proxies are detailed in the Proxy Statement.

Board of directors and corporate governance

• Dr. Roberts appointed to the Board as a Class I director, bringing extensive life sciences and leadership experience.

• Board and Nominating and Corporate Governance Committee recommended and approved the executive transition.